Aldeyra Therapeutics, Inc.

NASDAQ:ALDX

Biotechnology

Healthcare
$0.90 +3.01%

+$0.06 today

Market cap
$54.28M
Beta
1.19
P/E (TTM)
-4.2
EPS (TTM)
-$0.45
52W Low $1.07High $6.18

Volume 1.45M

Average 2.13M

ALDX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Aldeyra Therapeutics, Inc.NASDAQ: ALDX

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $2.41M fell 67.5% year over year, behind the -58.3% change in trailing-twelve-month research & development. Sequentially, it fell 44.0% from the prior quarter. Over 3 fiscal years it compounded at -18.4% a year.

Context

  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -67.5% toward the trailing-twelve-month pace of -58.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.41M-44.0% QoQ
Last fiscal yearDec 2025
$25.66M-46.8% YoY
LTMMar 2026
$20.65M-58.3% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-67.5%——
1 year-46.8%——
3-year CAGR-18.4%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
25.66M USD
Year-over-year change
-46.8%
4-year CAGR
-13.1%

Research & Development vs competitors

How ALDX compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -58.3% is the lowest of 10, against a peer median of +3.6%.
  • Over three fiscal years its annual growth of -18.4% compares with a peer median of +18.8%.
ALDX Competitors
Research & Development for ALDX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$126.01M USD-0.7%+67.6%—
CLLSCellectis S.A.LTM Mar 2026$94.68M USD+5.0%-1.4%139.0%
SLNSilence Therapeutics plcLTM Mar 2026$61.84M USD—+24.0%6710.8%
ANROAlto Neuroscience, Inc.LTM Mar 2026$55.94M USD+19.0%+24.4%—
ACIUAC Immune S.A.LTM Mar 2026CHF 52.18M CHF-17.6%-2.2%1409.6%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$49.38M USD+11.3%+45.0%—
CADLCandel Therapeutics, Inc.LTM Mar 2026$36.32M USD+88.9%+13.6%—
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$20.65M USD-58.3%-18.4%—
GNLXGenelux CorporationLTM Mar 2026$20.4M USD+3.6%+29.8%254962.5%
AMRNAmarin Corporation plcLTM Mar 2026$18.45M USD-6.9%-13.3%8.6%
MREOMereo BioPharma Group plcLTM Mar 2026$18.13M USD-12.8%-16.7%3625.8%
Peer median (excluding ALDX) —+3.6%+18.8%2517.7%

Competitors are the stored peer set for ALDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development44.94M47.31M29.46M48.22M25.66M
Selling, General & Admin11.28M15.37M13.34M11.89M9.6M
Operating Expenses56.22M62.68M42.79M60.12M35.27M
Depreciation & Amortization264.18K258.71K262.78K249.62K251.99K
EBITDA(55.77M)(60.07M)(35.21M)(53.68M)(31.69M)
EBITDA Margin—————
Operating Income(56.22M)(62.68M)(42.79M)(60.12M)(35.27M)
Operating Margin—————
Interest Income185.36K2.35M7.32M6.19M3.32M
Interest Expense1.74M1.69M2.07M1.93M1.91M
Other Income / Expenses(1.56M)655.35K5.25M4.27M1.42M
Income Before Tax(57.78M)(62.02M)(37.54M)(55.85M)(33.85M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(57.78M)(62.02M)(37.54M)(55.85M)(33.85M)
Net Margin—————
EPS (Basic)(1.07)(1.06)(0.64)(0.94)(0.56)
EPS (Diluted)(1.07)(1.06)(0.64)(0.94)(0.56)
Weighted Avg Shares54.04M58.41M58.94M59.48M60.06M
Weighted Avg Shares (Diluted)54.04M58.41M58.94M59.48M60.06M

Aldeyra Therapeutics, Inc.

NASDAQ:ALDX

Intrinsic Alpha fair value

Locked

Current Price

$0.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.